Abstract Number: 772 • 2014 ACR/ARHP Annual Meeting
RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic Gene Expression Subsets Shows Differential Expression of Non-Coding RNAs Regulating SSc Gene Expression
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease with a heterogenous and complex phenotype. Previously, our lab has identified four gene expression subsets (fibroproliferative,…Abstract Number: 770 • 2014 ACR/ARHP Annual Meeting
Detection of Proteins in Lung Tissues of Patients with Systemic Sclerosis Using Tissue Microarrays
Background/Purpose: Research on systemic sclerosis (SSc)-associated interstitial lung disease (ILD) has been hindered by the paucity of lung tissues, as SSc patients with lung involvement…Abstract Number: 765 • 2014 ACR/ARHP Annual Meeting
Gene-Gene Interaction of IRF5 and BLK Polymorphisms in US and Spanish Cohorts of Systemic Sclerosis (SSc)
Background/Purpose Systemic sclerosis (SSc) is a complex autoimmune disease and several genetic loci increasing SSc susceptibility have been identified with small to modest effect sizes.…Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…Abstract Number: 2716 • 2014 ACR/ARHP Annual Meeting
Development of a “Renal Crisis Prevention Card” As an Educational Tool Aimed at Improving Outcomes in High-Risk Patients with Systemic Sclerosis
Background/Purpose: Scleroderma renal crisis (SRC) is a devastating complication of SSc. The introduction of effective treatment with ACE inhibition (ACE-I) in 1979 dramatically reduced…Abstract Number: 2699 • 2014 ACR/ARHP Annual Meeting
Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts
Background/Purpose: SSc is a complex, diffuse, devastating health condition of vascular injury, inflammation and fibrosis resulting in multiple organ-system derangements with high impact on…Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting
Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting
Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity. Epidemiologic studies using large administrative databases often rely on the accuracy of…Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- Next Page »